233 related articles for article (PubMed ID: 10554098)
41. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles.
Kreuter J; Ramge P; Petrov V; Hamm S; Gelperina SE; Engelhardt B; Alyautdin R; von Briesen H; Begley DJ
Pharm Res; 2003 Mar; 20(3):409-16. PubMed ID: 12669961
[TBL] [Abstract][Full Text] [Related]
42. Doxorubicin does not spread systemically following a local injection into the eyelids of rabbits.
McLoon LK; Josephson K; Wirtschafter J
Curr Eye Res; 1999 Sep; 19(3):285-9. PubMed ID: 10487969
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetic evaluation of intraperitoneal doxorubicin in rats.
Nagai K; Nogami S; Egusa H; Konishi H
Pharmazie; 2014 Feb; 69(2):125-7. PubMed ID: 24640601
[TBL] [Abstract][Full Text] [Related]
44. Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study.
Aryal M; Vykhodtseva N; Zhang YZ; McDannold N
J Control Release; 2015 Apr; 204():60-9. PubMed ID: 25724272
[TBL] [Abstract][Full Text] [Related]
45. In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin.
Guo H; Zhang D; Li T; Li C; Guo Y; Liu G; Hao L; Shen J; Qi L; Liu X; Luan J; Zhang Q
J Pharm Sci; 2014 Mar; 103(3):987-93. PubMed ID: 24549734
[TBL] [Abstract][Full Text] [Related]
46. Conformation of surface-decorating dextran chains affects the pharmacokinetics and biodistribution of doxorubicin-loaded nanoparticles.
Alhareth K; Vauthier C; Bourasset F; Gueutin C; Ponchel G; Moussa F
Eur J Pharm Biopharm; 2012 Jun; 81(2):453-7. PubMed ID: 22465096
[TBL] [Abstract][Full Text] [Related]
47. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.
Choi JS; Piao YJ; Kang KW
Arch Pharm Res; 2011 Apr; 34(4):607-13. PubMed ID: 21544726
[TBL] [Abstract][Full Text] [Related]
48. Body distribution of 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after i.v. injections to mice.
Schroeder U; Schroeder H; Sabel BA
Life Sci; 2000; 66(6):495-502. PubMed ID: 10794066
[TBL] [Abstract][Full Text] [Related]
49. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery.
Calvo P; Gouritin B; Chacun H; Desmaële D; D'Angelo J; Noel JP; Georgin D; Fattal E; Andreux JP; Couvreur P
Pharm Res; 2001 Aug; 18(8):1157-66. PubMed ID: 11587488
[TBL] [Abstract][Full Text] [Related]
50. Nanoparticle technology for delivery of drugs across the blood-brain barrier.
Schroeder U; Sommerfeld P; Ulrich S; Sabel BA
J Pharm Sci; 1998 Nov; 87(11):1305-7. PubMed ID: 9811481
[TBL] [Abstract][Full Text] [Related]
51. Treatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticles.
Wohlfart S; Khalansky AS; Bernreuther C; Michaelis M; Cinatl J; Glatzel M; Kreuter J
Int J Pharm; 2011 Aug; 415(1-2):244-51. PubMed ID: 21641983
[TBL] [Abstract][Full Text] [Related]
52. Intracellular drug delivery using polysorbate 80-modified poly(D,L-lactide-co-glycolide) nanospheres to glioblastoma cells.
Tahara K; Kato Y; Yamamoto H; Kreuter J; Kawashima Y
J Microencapsul; 2011; 28(1):29-36. PubMed ID: 21171814
[TBL] [Abstract][Full Text] [Related]
53. Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles.
Verdun C; Brasseur F; Vranckx H; Couvreur P; Roland M
Cancer Chemother Pharmacol; 1990; 26(1):13-8. PubMed ID: 2322986
[TBL] [Abstract][Full Text] [Related]
54. Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model.
Arnold RD; Mager DE; Slack JE; Straubinger RM
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8856-65. PubMed ID: 16361575
[TBL] [Abstract][Full Text] [Related]
55. [Effect of diameter of adriamycin polybutylcyanoacrylate nanoparticles on liver targeting].
Shen LF; Wang X; Wang C; Zhao K; Liu XJ; Shen HJ
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):732-6, 741. PubMed ID: 17062941
[TBL] [Abstract][Full Text] [Related]
56. Nanoparticles based on disulfide-containing poly(β-amino ester) and zwitterionic fluorocarbon surfactant as a redox-responsive drug carrier for brain tumor treatment.
Feng R; Chen Q; Zhou P; Wang Y; Yan H
Nanotechnology; 2018 Dec; 29(49):495101. PubMed ID: 30211689
[TBL] [Abstract][Full Text] [Related]
57. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
[TBL] [Abstract][Full Text] [Related]
58. PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin.
Ryan GM; Kaminskas LM; Bulitta JB; McIntosh MP; Owen DJ; Porter CJH
J Control Release; 2013 Nov; 172(1):128-136. PubMed ID: 23954628
[TBL] [Abstract][Full Text] [Related]
59. Delivery of nanoparticles to the brain detected by fluorescence microscopy.
Reimold I; Domke D; Bender J; Seyfried CA; Radunz HE; Fricker G
Eur J Pharm Biopharm; 2008 Oct; 70(2):627-32. PubMed ID: 18577452
[TBL] [Abstract][Full Text] [Related]
60. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles.
Tian XH; Lin XN; Wei F; Feng W; Huang ZC; Wang P; Ren L; Diao Y
Int J Nanomedicine; 2011; 6():445-52. PubMed ID: 21445277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
